Skip to main content

Articles

Page 1 of 64

  1. Migraine is a disabling neurological disorder, characterized by recurrent headaches. During migraine attacks, individuals often experience sensory symptoms such as cutaneous allodynia which indicates the prese...

    Authors: Jérémy Signoret-Genest, Maxime Barnet, François Gabrielli, Youssef Aissouni, Alain Artola, Radhouane Dallel, Myriam Antri, Philip Tovote and Lénaïc Monconduit
    Citation: The Journal of Headache and Pain 2023 24:165
    Content type: Research Published on:

  2. Chronic migraine can be a profoundly disabling disorder that may be treated with preventive medications. However, uncertainty remains as to which preventive medication is the most effective. We present a netwo...

    Authors: Seyran Naghdi, Martin Underwood, Jason Madan, Anna Brown, Callum Duncan, Manjit Matharu, Aiva Aksentyte, Natasha Davies, Sophie Rees, Andrew Cooklin, Amy Grove and Hema Mistry
    Citation: The Journal of Headache and Pain 2023 24:164
    Content type: Research Published on:

  3. The brain functional network topology in new daily persistent headache (NDPH) is not well understood. In this study, we aim to assess the cortical functional network topological characteristics of NDPH using n...

    Authors: Dong Qiu, Zhaoli Ge, Yanliang Mei, Wei Wang, Zhonghua Xiong, Xiaoshuang Li, Ziyu Yuan, Peng Zhang, Mantian Zhang, Xin Liu, Yaqing Zhang, Xueying Yu, Hefei Tang and Yonggang Wang
    Citation: The Journal of Headache and Pain 2023 24:161
    Content type: Research Published on:

  4. In this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies. Based on current real-life studies and analysis of practical ...

    Authors: Marta Waliszewska-Prosół, Doga Vuralli and Paolo Martelletti
    Citation: The Journal of Headache and Pain 2023 24:163
    Content type: Editorial Published on:

  5. Migraine is the world’s second most common disabling disorder, affecting 15% of UK adults and costing the UK over £1.5 billion per year. Several costly new drugs have been approved by National Institute for He...

    Authors: Hema Mistry, Seyran Naghdi, Martin Underwood, Callum Duncan, Jason Madan and Manjit Matharu
    Citation: The Journal of Headache and Pain 2023 24:162
    Content type: Research Published on:

  6. Cutaneous allodynia is highly prevalent among migraineurs and is associated with a poor prognosis. The Allodynia Symptom Checklist (ASC-12) is a comprehensive questionnaire to identify the presence and severit...

    Authors: Tetiana Marusich, Tibor M Szikszay, Anne Sennholz, Kerstin Luedtke and Gabriela F. Carvalho
    Citation: The Journal of Headache and Pain 2023 24:160
    Content type: Research Published on:

  7. Primary headache disorder is a known risk factor for stroke in women and usually improves during the first trimester of pregnancy. However, despite this, some women develop headaches during pregnancy (G-HA), a...

    Authors: Ki-Woong Nam, Sungyeon Ha, Min-Jeong Oh, Kyungmi Oh, Chi Kyung Kim, Geum Joon Cho, Young Seo Kim and Cheryl D. Bushnell
    Citation: The Journal of Headache and Pain 2023 24:159
    Content type: Research Published on:

  8. Migraine is a primary headache, which has been producing heavy disease burden globally. There is no data on the incidence of migraine among women of childbearing age worldwide, including China. This study aime...

    Authors: Zhuanzhuan Fan, Jian Kang, Wenting Li, Zhiyong Wang, Huifen Qiao and Fei Xu
    Citation: The Journal of Headache and Pain 2023 24:158
    Content type: Research Published on:

  9. Galcanezumab has shown efficacy and effectiveness in the treatment of episodic and chronic migraine (CM), however, the population represented in randomized clinical trials (RCTs) differs from the population ob...

    Authors: Victor Obach, Fernando Velasco, Rocio Alvarez Escudero, María Martín Bujanda, Sonsoles Aranceta, Neus Fabregat, Teresa Marco, Aintzine Ruisanchez, Natalia Roncero, Ane Mínguez-Olaondo, Marta Ruibal, Daniel Guisado-Alonso, Antia Moreira, Elisa Cuadrado-Godia, Amaya Echeverria, Izaro Kortazar Zubizarreta…
    Citation: The Journal of Headache and Pain 2023 24:157
    Content type: Research Published on:

  10. Authors: Xin-yu Li, Cheng-hao Yang, Jia-jie Lv, Hui Liu, Lu-yu Zhang, Min-yi Yin, Zhi-lin Guo and Ru-hong Zhang
    Citation: The Journal of Headache and Pain 2023 24:156
    Content type: Correction Published on:

    The original article was published in The Journal of Headache and Pain 2023 24:126

  11. Eptinezumab demonstrated efficacy in adults with migraine and prior preventive treatment failures in the placebo-controlled phase of the DELIVER clinical trial; its long-term effectiveness in this population h...

    Authors: Messoud Ashina, Stewart J. Tepper, Astrid Gendolla, Bjørn Sperling, Anders Ettrup, Mette Krog Josiassen and Amaal J. Starling
    Citation: The Journal of Headache and Pain 2023 24:155
    Content type: Research Published on:

  12. Women are disproportionately affected by migraine, representing up to 75% of all migraine cases. This discrepancy has been proposed to be influenced by differences in hormone levels between the sexes. One such...

    Authors: Aida Maddahi, Karin Warfvinge, Anja Holm, Jacob C. A. Edvinsson, Philip Victor Reducha, Spyridoula Kazantzi, Kristian A. Haanes and Lars Edvinsson
    Citation: The Journal of Headache and Pain 2023 24:154
    Content type: Research Published on:

  13. New acute and preventive migraine medications are available, but data on current treatment patterns are limited. This study describes migraine treatment patterns among patients initiating novel acute migraine ...

    Authors: Zifan Zhou, Robert Urman, Karminder Gill, Andrew S. Park, Fiston Vuvu, Leah B. Patel, Jingsong Lu, Rolin L. Wade, Lindsay Frerichs and Mark E. Bensink
    Citation: The Journal of Headache and Pain 2023 24:153
    Content type: Research Published on:

  14. Randomized clinical trials have demonstrated efficacy and safety of erenumab. The aim of this study is to evaluate the effectiveness and safety of erenumab in a real-world setting in French patients with migra...

    Authors: M. Lanteri-Minet, R. Fabre, C. Martin, K. Pradat, A. Alchaar, E. Bozzolo, M. L. Duchene, E. K. Van Obberghen, A. Donnet and D. Fontaine
    Citation: The Journal of Headache and Pain 2023 24:152
    Content type: Research Published on:

  15. Individuals with migraine frequently experience pre- and post-headache symptoms. This analysis aimed to characterize the relative frequency and burden of pre- and post-headache symptoms in people with migraine...

    Authors: Richard B. Lipton, Michel Lanteri-Minet, Elizabeth Leroux, Aubrey Manack Adams, Janette Contreras-De Lama, Michael L. Reed, Kristina M. Fanning and Dawn C. Buse
    Citation: The Journal of Headache and Pain 2023 24:151
    Content type: Research Published on:

  16. Medication overuse headache (MOH) is a secondary headache that accompanies chronic migraine. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most frequently used analgesics worldwide and they are known t...

    Authors: Hale Gök Dağıdır, Elif Topa, Doga Vuralli and Hayrunnisa Bolay
    Citation: The Journal of Headache and Pain 2023 24:150
    Content type: Research Published on:

  17. Serum neurofilament light chain (sNfL) can reflect nerve damage. Whether migraine can cause neurological damage remain unclear. This study assesses sNfL levels in migraine patients and explores whether there i...

    Authors: Jie Fang, Jielong Wu, Tengkun Zhang, Xiaodong Yuan, Jiedong Zhao, Liangcheng Zheng, Ganji Hong, Lu Yu, Qing Lin, Xingkai An, Chuya Jing, Qiuhong Zhang, Chen Wang, Zhanxiang Wang and Qilin Ma
    Citation: The Journal of Headache and Pain 2023 24:149
    Content type: Research Published on:

  18. Migraine is a common disabling neurological disorder with severe physical and psychological damage, but there is a lack of convenient and effective non-invasive early prediction methods. This study aimed to de...

    Authors: Shaojie Duan, Hui Xia, Tao Zheng, Guanglu Li, Zhiying Ren, Wenyan Ding, Ziyao Wang and Zunjing Liu
    Citation: The Journal of Headache and Pain 2023 24:148
    Content type: Research Published on:

  19. Preliminary evidence suggests that several headache disorders may be associated with glymphatic dysfunction. However, no studies have been conducted to examine the glymphatic activity in migraine chronification.

    Authors: Xue Zhang, Wei Wang, Xiaoyan Bai, Xueyan Zhang, Ziyu Yuan, Bingjie Jiao, Yingkui Zhang, Zhiye Li, Peng Zhang, Hefei Tang, Yaqing Zhang, Xueying Yu, Ruiliang Bai, Yonggang Wang and Binbin Sui
    Citation: The Journal of Headache and Pain 2023 24:147
    Content type: Research Published on:

  20. Migraine is a brain disorder with recurrent headache attacks and altered sensory processing. Introvision is a self-regulation method based on mindfulness-like perception techniques, developed at the University...

    Authors: Monika Empl, Sonja Löser, Petra Spille, Agnieszka Rozwadowska, Ruth Ruscheweyh and Andreas Straube
    Citation: The Journal of Headache and Pain 2023 24:146
    Content type: Research Published on:

  21. The present study aimed to compare sex differences in the clinical manifestations related to dependence behaviors in medication-overuse headache (MOH).

    Authors: Yen-Feng Wang, Yi-Shiang Tzeng, Chia-Chun Yu, Yu-Hsiang Ling, Shih-Pin Chen, Kuan-Lin Lai, Wei-Ta Chen and Shuu-Jiun Wang
    Citation: The Journal of Headache and Pain 2023 24:145
    Content type: Research Published on:

  22. Monoclonal antibodies (mAbs) targeting the Calcitonin Gene-Related Peptide (CGRP) pathway are safe and effective treatments for migraine prevention. However, the high cost of these novel therapies has led to r...

    Authors: Ja Bin Hong, Kristin Sophie Lange, Mira Fitzek, Lucas Hendrik Overeem, Paul Triller, Anke Siebert, Uwe Reuter and Bianca Raffaelli
    Citation: The Journal of Headache and Pain 2023 24:144
    Content type: Research Published on:

  23. The 2030 Agenda for Sustainable Development sets out, through 17 Sustainable Development Goals (SDGs), a path for the prosperity of people and the planet. SDG 3 in particular aims to ensure healthy lives and p...

    Authors: Paolo Martelletti, Matilde Leonardi, Messoud Ashina, Rami Burstein, Soo-Jin Cho, Augustina Charway-Felli, David W. Dodick, Raquel Gil-Gouveia, Licia Grazzi, Christian Lampl, Antoinette MaassenVanDenBrink, Mia T. Minen, Dimos Dimitrios Mitsikostas, Jes Olesen, Mayowa Ojo Owolabi, Uwe Reuter…
    Citation: The Journal of Headache and Pain 2023 24:140
    Content type: Review Published on:

  24. BMP7 has been shown to have neuroprotective effects and to alleviate demyelination. However, its role in trigeminal neuralgia (TN) has not been well investigated. The current study aims to determine whether BM...

    Authors: Kai Chen, Xiaojin Wei, Ruixuan Wang, Lin Yang, Dingquan Zou and Yaping Wang
    Citation: The Journal of Headache and Pain 2023 24:143
    Content type: Research Published on:

  26. Chronic primary pain (CPP) is an intractable pain of unknown cause with significant emotional distress and/or dysfunction that is a leading factor of disability globally. The lack of a suitable animal model th...

    Authors: An-Ran Liu, Zhen-Jia Lin, Ming Wei, Yuan Tang, Hui Zhang, Xiang-Ge Peng, Ying Li, Yu-Fan Zheng, Zhi Tan, Li-Jun Zhou and Xia Feng
    Citation: The Journal of Headache and Pain 2023 24:141
    Content type: Research Published on:

  27. To determine specific resting-state network patterns underlying alterations in chronic migraine, we employed oscillatory connectivity and machine learning techniques to distinguish patients with chronic migrai...

    Authors: Fu-Jung Hsiao, Wei-Ta Chen, Yu-Te Wu, Li-Ling Hope Pan, Yen-Feng Wang, Shih-Pin Chen, Kuan-Lin Lai, Gianluca Coppola and Shuu-Jiun Wang
    Citation: The Journal of Headache and Pain 2023 24:139
    Content type: Research Published on:

  28. Amygdala, an essential element of the limbic system, has served as an important structure in pain modulation. There is still a lack of clarity about altered cerebral perfusion of amygdala in migraine. This stu...

    Authors: Xiaoyan Bai, Wei Wang, Xueyan Zhang, Zhangxuan Hu, Xue Zhang, Yingkui Zhang, Hefei Tang, Yaqing Zhang, Xueying Yu, Ziyu Yuan, Peng Zhang, Zhiye Li, Xun Pei, Yonggang Wang and Binbin Sui
    Citation: The Journal of Headache and Pain 2023 24:138
    Content type: Research Published on:

  29. The significance of hyperactive astrocytes in neuropathic pain is crucial. However, the association between medullary astrocytes and trigeminal neuralgia (TN)-related pain processing is unclear. Here, we exami...

    Authors: Elina KC, Jaisan Islam, Hyong Kyu Kim and Young Seok Park
    Citation: The Journal of Headache and Pain 2023 24:137
    Content type: Research Published on:

  30. Cluster headache is a severe and disabling primary headache disorder. Galcanezumab is a monoclonal antibody against calcitonin gene-related peptide and a preventive therapy for episodic cluster headache. Howev...

    Authors: Yooha Hong, Mi-Kyoung Kang, Heui-Soo Moon, Byung-Kun Kim and Soo-Jin Cho
    Citation: The Journal of Headache and Pain 2023 24:136
    Content type: Research Published on:

  31. Triptans are effective for many migraine patients, but some do not experience adequate efficacy and tolerability. The European Headache Federation (EHF) has proposed that patients with lack of efficacy and/or ...

    Authors: Ruth Ruscheweyh, Gudrun Gossrau, Thomas Dresler, Tobias Freilinger, Stefanie Förderreuther, Charly Gaul, Torsten Kraya, Lars Neeb, Victoria Ruschil, Andreas Straube, Jörg Scheidt and Tim Patrick Jürgens
    Citation: The Journal of Headache and Pain 2023 24:135
    Content type: Research Published on:

  32. Topiramate is a repurposed first-line treatment for migraine prophylaxis. The aim of this systematic review and meta-analysis is to critically re-appraise the existing evidence supporting the efficacy and tole...

    Authors: Bianca Raffaelli, David García-Azorín, Deirdre M. Boucherie, Faisal Mohammad Amin, Christina I. Deligianni, Raquel Gil-Gouveia, Sarah Kirsh, Christian Lampl, Simona Sacco, Derya Uluduz, Jan Versijpt, Antoinette MaassenVanDenBrink, Dena Zeraatkar, Margarita Sanchez-del-Rio and Uwe Reuter
    Citation: The Journal of Headache and Pain 2023 24:134
    Content type: Review Published on:

  33. Neuroimaging has revealed that migraine is linked to alterations in both the structure and function of the brain. However, the relationship of these changes with aging has not been studied in detail. Here we e...

    Authors: Rafael Navarro-González, David García-Azorín, Ángel L. Guerrero-Peral, Álvaro Planchuelo-Gómez, Santiago Aja-Fernández and Rodrigo de Luis-García
    Citation: The Journal of Headache and Pain 2023 24:133
    Content type: Research Published on:

  34. Although acute headache following COVID-19 vaccination is widely acknowledged, the long-term progression of these headaches remains poorly understood. Our objective was to identify various phenotypes of prolon...

    Authors: Arife Çimen Atalar, Ayşe Nur Özdağ Acarlı, Betül Baykan, Paolo Martelletti, Hayrunnisa Bolay, Mustafa Ertaş, Esme Ekizoğlu, Ömer Karadaş, Burcu Polat, Işıl Yazıcı Gençdal, David Garcia Azorin, Dimos Mitsikostas, Loukia Apostolakopoulou, Hamit Genç, Pınar Yalınay Dikmen, Esra Acıman Demirel…
    Citation: The Journal of Headache and Pain 2023 24:132
    Content type: Research Published on:

  36. Migraine is a disorder associated with neuropeptide release, pain and inflammation. Tau protein has recently been linked to inflammatory diseases and can be influenced by neuropeptides such as CGRP, a key neur...

    Authors: Lucas Hendrik Overeem, Bianca Raffaelli, Robert Fleischmann, Marie Süße, Antje Vogelgesang, Aleksandra Maleska Maceski, Athina Papadopoulou, Klemens Ruprecht, Wendy Su, Mirja Koch, Anke Siebert, Michal Arkuszewski, Nadia Tenenbaum, Jens Kuhle and Uwe Reuter
    Citation: The Journal of Headache and Pain 2023 24:130
    Content type: Research Published on:

  37. Novel disease-specific and mechanism-based treatments sharing good evidence of efficacy for migraine have been recently marketed. However, reimbursement by insurers depends on treatment failure with classic an...

    Authors: Christina I. Deligianni, Simona Sacco, Esme Ekizoglu, Derya Uluduz, Raquel Gil-Gouveia, Antoinette MaassenVanDenBrink, Raffaele Ornello, Margarita Sanchez-del-Rio, Uwe Reuter, Jan Versijpt, Tessa de Vries, Muizz Hussain, Dena Zeraatkar and Christian Lampl
    Citation: The Journal of Headache and Pain 2023 24:128
    Content type: Review Published on:

  38. Intranasal agents may be ideal for the treatment of migraine patients. Many new acute intranasal-specific therapies have been developed, but few of them have been directly compared. The aim of this network met...

    Authors: Guanglu Li, Shaojie Duan, Tiantian Zhu, Zhiying Ren, Hui Xia, Ziyao Wang, Lei Liu and Zunjing Liu
    Citation: The Journal of Headache and Pain 2023 24:129
    Content type: Review Published on:

  39. Headaches are the most common complaints among pediatric populations. Determining the cause and appropriate treatment for headaches may be challenging and costly, and the impact of headaches on the lives of pa...

    Authors: S. Ombashi, E. Tsangaris, A. G. Heeres, V. van Roey, R. F. Neuteboom, M. L. C. van Veelen-Vincent, K. Jansson, I. M. J. Mathijssen, A. F. Klassen and S. L. Versnel
    Citation: The Journal of Headache and Pain 2023 24:127
    Content type: Review Published on:

  40. In recent years, headache disorders have garnered significant attention as a pressing global health issue. This concern is especially pronounced in low- to middle-income countries and exhibits a notable increa...

    Authors: Xin-yu Li, Cheng-hao Yang, Jia-jie Lv, Hui Liu, Lu-yu Zhang, Min-yi Yin, Zhi-lin Guo and Ru-hong Zhang
    Citation: The Journal of Headache and Pain 2023 24:126
    Content type: Research Published on:

    The Correction to this article has been published in The Journal of Headache and Pain 2023 24:156

  41. Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review f...

    Authors: Alejandro Labastida-Ramírez, Edoardo Caronna, Cédric Gollion, Emily Stanyer, Austeja Dapkute, Diana Braniste, Hoda Naghshineh, Liga Meksa, Nino Chkhitunidze, Tamari Gudadze, Patricia Pozo-Rosich, Rami Burstein and Jan Hoffmann
    Citation: The Journal of Headache and Pain 2023 24:125
    Content type: Review Published on:

  42. There is a bidirectional link between sleep and migraine, however causality is difficult to determine. This study aimed to investigate this relationship using data collected from a smartphone application.

    Authors: Emily C. Stanyer, Jack Brookes, Jia Rong Pang, Alexandre Urani, Philip R. Holland and Jan Hoffmann
    Citation: The Journal of Headache and Pain 2023 24:123
    Content type: Research Published on:

  43. Although the involvement of calcitonin gene-related peptide (CGRP) in migraines is well-established, its specific role in investigating the aura phase, which often precedes the headache, remains largely unexpl...

    Authors: Haidar M. Al-Khazali, Håkan Ashina, Astrid Wiggers, Kathrine Rose, Afrim Iljazi, Rune Häckert Christensen, Henrik Winther Schytz, Faisal Mohammad Amin and Messoud Ashina
    Citation: The Journal of Headache and Pain 2023 24:124
    Content type: Research Published on:

  44. Migraine, a complex brain disorder, is regarded as a possible clinical manifestation of brain energy dysfunction. The trigeminovascular system is considered the basis for the pathogenesis of migraine, hence we...

    Authors: Wei Xie, Ruibing Li, Wenjing Tang, Zhenjie Ma, Shuai Miao, Chenhao Li, Chunxiao Yang, Bozhi Li, Tao Wang, Zihua Gong, Yue Zhou and Shengyuan Yu
    Citation: The Journal of Headache and Pain 2023 24:122
    Content type: Research Published on:

  45. Treatment for cluster headache is currently based on a trial-and-error approach. The available preventive treatment is unspecific and based on few and small studies not adhering to modern standards. Therefore,...

    Authors: Nunu Laura Timotheussen Lund, Anja Sofie Petersen, Rolf Fronczek, Jacob Tfelt-Hansen, Andrea Carmine Belin, Tore Meisingset, Erling Tronvik, Anna Steinberg, Charly Gaul and Rigmor Højland Jensen
    Citation: The Journal of Headache and Pain 2023 24:121
    Content type: Consensus Article Published on:

  46. Migraine is a highly prevalent primary headache disorder and a leading cause of disability. Difficulties in access to care during diagnostic and therapeutic journey contribute to the disease burden. Several ta...

    Authors: Gloria Vaghi, Roberto De Icco, Cristina Tassorelli, Peter J. Goadsby, Teófila Vicente-Herrero and Elena Ruiz de la Torre
    Citation: The Journal of Headache and Pain 2023 24:120
    Content type: Research Published on:

  47. Headache disorders are widely prevalent and pose a considerable economic burden on individuals and society. Globally, misdiagnosis and inadequate treatment of primary headache disorders remain significant chal...

    Authors: Huanxian Liu, Ming Dong, Kaiming Liu, Zhihua Jia, Wei Gui, Yingying Cheng, Yudan Lv, Kang Qu, Hongru Zhao, Jianjun Chen, Dan Zhang, Zhiliang Fan, Xiaosu Yang, Dongmei Hu, Hongyan Xie, Mingxin Li…
    Citation: The Journal of Headache and Pain 2023 24:119
    Content type: Research Published on:

  48. Central sensitisation is an important mechanism in migraine chronification. It is presumed to occur in second and third order neurons sequentially, resulting in an analogous spatial distribution of cutaneous a...

    Authors: Judith A. Pijpers, Dennis A. Kies, Erik W. van Zwet, Irene de Boer and Gisela M. Terwindt
    Citation: The Journal of Headache and Pain 2023 24:118
    Content type: Research Published on:

  49. Adipokines, including adiponectin, are implicated in nociceptive pain; however, the underlying cellular and molecular mechanisms remain unknown.

    Authors: Yuan Zhang, Yuan Wei, Tingting Zheng, Yu Tao, Yufang Sun, Dongsheng Jiang and Jin Tao
    Citation: The Journal of Headache and Pain 2023 24:117
    Content type: Research Published on:

  50. Data are limited regarding the combined impact of headache frequency and failure of preventive medication (efficacy and/or tolerability) on the humanistic/economic burden of migraine.

    Authors: Dawn C. Buse, Patricia Pozo-Rosich, Laure Dupont-Benjamin, Bridget L. Balkaran, Lulu Lee, Adam Jauregui, Pranav Gandhi, Mousam Parikh and Uwe Reuter
    Citation: The Journal of Headache and Pain 2023 24:115
    Content type: Research Published on:
Submit manuscript

Official journal of

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    7.1 - 5-year Impact Factor
    2.002 - SNIP (Source Normalized Impact per Paper)
    1.593 - SJR (SCImago Journal Rank)

    2022 Speed
    3 days submission to first editorial decision for all manuscripts (Median)
    49 days submission to accept (Median)

    2022 Usage
    4,377,089 downloads
    9,457 Altmetric mentions

  • ISSN: 1129-2377 (electronic)
  • ISSN: 1129-2369 (print)

Related reading

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us